WallStreetZenWallStreetZen

NASDAQ: NXGL
Nexgel Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell NXGL stock?

Based on 1 analyst offering ratings for Nexgel Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NXGL stock forecasts and price targets.

NXGL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-24

1 of 1

Forecast return on equity

Is NXGL forecast to generate an efficient return?

Company
70.32%
Industry
23.5%
Market
168.87%
NXGL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NXGL forecast to generate an efficient return on assets?

Company
13.16%
Industry
17%
NXGL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NXGL earnings per share forecast

What is NXGL's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.12
Avg 2 year Forecast
$0.41
Avg 3 year Forecast
$0.30

NXGL revenue forecast

What is NXGL's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$16.1M+33.46%
Avg 2 year Forecast
$24.8M+105.14%
Avg 3 year Forecast
$26.6M+120.74%
NXGL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NXGL revenue growth forecast

How is NXGL forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
32.02%
Industry
8.36%
Market
13.54%
NXGL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NXGL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NXGL vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
NXGL$0.28N/AN/AHold
GCTK$2.45N/AN/A
LUCY$0.83N/AN/AHold
CUPR$3.20N/AN/A
RGNT$1.88N/AN/A
View Top Medical Stocks

Nexgel Stock Forecast FAQ

Is Nexgel Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NXGL) stock is to Hold NXGL stock.

Out of 1 analyst, 0 (0%) are recommending NXGL as a Strong Buy, 0 (0%) are recommending NXGL as a Buy, 1 (100%) are recommending NXGL as a Hold, 0 (0%) are recommending NXGL as a Sell, and 0 (0%) are recommending NXGL as a Strong Sell.

If you're new to stock investing, here's how to buy Nexgel stock.

What is NXGL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NXGL) Nexgel's current Earnings Per Share (EPS) is -$0.71. On average, analysts forecast that NXGL's EPS will be -$0.12 for 2026, with the lowest EPS forecast at -$0.12, and the highest EPS forecast at -$0.13. On average, analysts forecast that NXGL's EPS will be $0.41 for 2027, with the lowest EPS forecast at $0.39, and the highest EPS forecast at $0.42. In 2028, NXGL's EPS is forecast to hit $0.30 (min: $0.28, max: $0.30).

What is NXGL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NXGL) forecast ROE is 70.32%, which is considered strong.

What is NXGL's earnings growth forecast for 2026-2028?

(NASDAQ: NXGL) Nexgel's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 28.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.19%.

Nexgel's earnings in 2026 is -$6,185,000.On average, 3 Wall Street analysts forecast NXGL's earnings for 2026 to be -$1,193,114, with the lowest NXGL earnings forecast at -$1,146,325, and the highest NXGL earnings forecast at -$1,228,206. On average, 3 Wall Street analysts forecast NXGL's earnings for 2027 to be $3,977,047, with the lowest NXGL earnings forecast at $3,821,084, and the highest NXGL earnings forecast at $4,094,018.

In 2028, NXGL is forecast to generate $2,883,359 in earnings, with the lowest earnings forecast at $2,770,286 and the highest earnings forecast at $2,968,163.

What is NXGL's revenue growth forecast for 2026-2028?

(NASDAQ: NXGL) Nexgel's forecast annual revenue growth rate of 32.02% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.

Nexgel's revenue in 2026 is $12,066,000.On average, 3 Wall Street analysts forecast NXGL's revenue for 2026 to be $156,966,617, with the lowest NXGL revenue forecast at $150,806,094, and the highest NXGL revenue forecast at $161,577,262. On average, 3 Wall Street analysts forecast NXGL's revenue for 2027 to be $241,274,155, with the lowest NXGL revenue forecast at $231,818,921, and the highest NXGL revenue forecast at $248,370,453.

In 2028, NXGL is forecast to generate $259,629,004 in revenue, with the lowest revenue forecast at $249,452,444 and the highest revenue forecast at $267,271,172.

What is NXGL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NXGL) forecast ROA is 13.16%, which is lower than the forecast US Medical Instruments & Supplies industry average of 17%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.